Pyrrolo[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase
作者:Frank Ruebsam、Stephen E. Webber、Martin T. Tran、Chinh V. Tran、Douglas E. Murphy、Jingjing Zhao、Peter S. Dragovich、Sun Hee Kim、Lian-Sheng Li、Yuefen Zhou、Qing Han、Charles R. Kissinger、Richard E. Showalter、Matthew Lardy、Amit M. Shah、Mei Tsan、Rupal Patel、Laurie A. LeBrun、Ruhi Kamran、Maria V. Sergeeva、Darian M. Bartkowski、Thomas G. Nolan、Daniel A. Norris、Leo Kirkovsky
DOI:10.1016/j.bmcl.2008.04.066
日期:2008.6
Pyrrolo[1,2-b]pyridazin-2-one analogs were discovered as a novel class of inhibitors of genotype 1 HCV NS5B polymerase. Structure-based design led to the discovery of compound 3 k, which displayed potent inhibitory activities in biochemical and replicon assays (IC(50) (1b)<10nM; EC(50) (1b)=12 nM) as well as good stability towards human liver microsomes (HLM t(1/2)>60 min).
HCV NS5B polymerase inhibitors 3: Synthesis and in vitro activity of 3-(1,1-dioxo-2H-[1,2,4]benzothiadiazin-3-yl)-4-hydroxy-2H-quinolizin-2-one derivatives
作者:Guangyi Wang、Laiguo Zhang、Xiaomin Wu、Debasis Das、Donald Ruhrmund、Lisa Hooi、Shawn Misialek、P.T. Ravi Rajagopalan、Brad O. Buckman、Karl Kossen、Scott D. Seiwert、Leonid Beigelman
DOI:10.1016/j.bmcl.2009.05.021
日期:2009.8
3-(1,1-Dioxo-2H-[1,2,4]benzothiadiazin-3-yl)-4-hydroxy-2H-quinolizin-2-one derivatives as potential anti-HCV drugs targeting NS5B polymerase have been investigated. Their synthesis, HCV NS5B polymerase inhibition, and replicon activity are discussed. (C) 2009 Elsevier Ltd. All rights reserved.
NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION
申请人:Intermune, Inc.
公开号:EP2283002A2
公开(公告)日:2011-02-16
[EN] NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION<br/>[FR] NOUVEAUX INHIBITEURS DE RÉPLICATION DU VIRUS DE L'HÉPATITE C
申请人:INTERMUNE INC
公开号:WO2009134616A2
公开(公告)日:2009-11-05
The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.